Venatorx and Menarini enter commercial agreement for cefepime-taniborbactam
January 11, 2024Sales and Marketing Infections and infestations, Menarini Group, Venatorx Pharmaceuticals, cefepime-taniborbactam, collaboration
Venatorx Pharmaceuticals and Menarini Group have announced that they have entered into a commercial agreement valid in 96 countries in …
Isomorphic Labs to collaborate with Eli Lilly
January 11, 2024Research and Development AI, Eli Lilly, Isomorphic Labs, Pharmacy, drug discovery
Isomorphic Labs has announced that it has entered into a strategic research collaboration with Eli Lilly and Company, marking the …
Novo Nordisk shares positive results from COMBINE 3 phase 3a trial
January 10, 2024Research and Development Diabetes, IcoSema, Novo Nordisk, clinical trial, diabetes
Novo Nordisk has shared topline results from the COMBINE 3 phase 3a trial of once-weeklly IcoSema, a fixed-ration combination treatment …
Merck to acquire Harpoon Therapeutics for approximately $680m
January 10, 2024Business Services Harpoon Therapeutics, MSD, Merck, Oncology, acquisition
Merck (known as MSD outside of the US and Canada) and Harpoon Therapeutics have announced that they have entered a …
Fate Therapeutics initiates phase 1 trial for solid tumour treatment
January 9, 2024Research and Development Fate Therapeutics, Oncology, solid tumours
Fate Therapeutics has announced that it has begun enrollment for the phase 1 clinical trial of FT825/ONO-8250, a multiplexed-engineered, chimeric …
GSK to acquire Aiolos Bio for $1bn
January 9, 2024Business Services Aiolos Bio, GSK, Pharmacy, acquisition
GSK and Aiolos Bio have announced that they have entered into an agreement for GSK to acquire Aiolos for an …
Consilient Health to launch Cytisine smoking cessation treatment in UK
January 8, 2024Sales and Marketing Cytisine, Smoking Cessation, consilient health, smoking cessation
Consilient Health has announced that it plans to launch Cytisine 1.5mg tablets in the UK on 22 January 2024. The …
Calypso Biotech to be acquired by Novartis for $250m
January 8, 2024Business Services Calypso Biotech, Immunology, Novartis, acquisition
Calypso Biotech has announced that it has entered into an agreement to be acquired by Novartis. The company’s shareholders will …
Eli Lilly launches digital healthcare process
January 5, 2024Medical Communications Diabetes, Eli Lilly, Obesity, diabetes, obesity
Eli Lilly has announced its new digital healthcare experience, LillyDirect, which will benefit patients in the US with obesity, migraine …
Rhythm Pharmaceuticals and LG Chem Life Sciences enter license agreement
January 5, 2024Medical Communications LG Chem Life Sciences, License Agreement, Pharmacy, Rhythm Pharmaceuticals, clinical trial
Rhythm Pharmaceuticals and LG Chem Life Sciences have announced that they have entered into a global licensing agreement for LB54640, …
Renovos Biologics gains FDA Breakthrough Device Designation for Renovite
January 4, 2024Medical Communications FDA, Musculo-skeletal disorder, Renovos Biologics, breakthrough device designation
Renovos Biologics has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its lead …
Galapagos and BridGene Biosciences enter collaboration for oncology drug discovery
January 4, 2024Research and Development BridGene Biosciences, Galapagos, Oncology, drug discovery, oncology
Galapagos NV and BridGene Biosciences have announced that they have entered into a strategic collaboration and licensing agreement for the …
C4X receives $11m milestone payment from AstraZeneca
January 3, 2024Sales and Marketing AstraZeneca, C4X, C4X Discovery, Chronic Diseases
C4X Discovery Holdings has announced that it has received a milestone payment of $11m from AstraZeneca which has been triggered …
Proteome Sciences completes new facility in San Diego, US
January 3, 2024Manufacturing and Production Pharmacy, Proteome Sciences, facility, san diego
Proteome Sciences has announced that it has completed the installation and set up of equipment in its new laboratory facility …
AstraZeneca and Sanofi’s Beyfortus approved in China
January 2, 2024Research and Development AstraZeneca, Beyfortus, China, Immunology, Sanofi
AstraZeneca and Sanofi have announced that Beyfortus (nirsevimab) has been approved in China for the prevention of respiratory syncytial virus …
Astellas and Elpiscience enter collaboration for novel bispecific macrophage engager
January 2, 2024Research and Development Astellas, Cancer, Elpiscience, Oncology, bispecific macrophage
Elpiscience Biopharma and Astellas Pharma have announced that they have entered into a research collaboration and license agreement for novel …
Calliditas Therapeutics gains FDA approval of Tarpeyo
December 22, 2023Medical Communications Calliditas, FDA, Nephrology, kidneys
Calliditas Therapeutics has announced that the US Food and Drug Administration (FDA) has approved Tarpeyo (budesonide) delayed release capsules to …
FDA approves AstraZeneca and Ionis’s Wainua
December 22, 2023Medical Communications AstraZeneca, FDA, Ionis, Neurology, Wainua
AstraZeneca and Ionis have announced that the US Food and Drug Administration (FDA) has approved Wainua (eplontersen) for the treatment …
Ocelot Bio gains FDA ODD for OCE-205 for ascites treatment
December 21, 2023Research and Development Gastrointestinal tract, Ocelot Bio, ascites
Ocelot Bio has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to OCE-205 …
Tracon Pharmaceuticals shares update on ENVASARC phase 2 trial
December 21, 2023Research and Development ENVASARC, Pharmacy, Tracon Pharmaceuticals, clinical trial
Tracon Pharmaceuticals has shared an update from the ongoing phase 2 ENVASARC trial, which has now enrolled more than 70 …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
